Oral platinum analogue JM216, a radiosensitizer in oxic murine cells

International Journal of Radiation Biology

Volumn 72, Issue 6, 1997, Pages 675-683

  Van De Vaart, P J M ^a   Klaren, H M ^a   Hofland, I ^a   Begg, A C ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GLUTATHIONE; RADIOSENSITIZING AGENT; SATRAPLATIN; SODIUM CHLORIDE;

ANIMAL CELL; ARTICLE; CELL KILLING; CELL SURVIVAL; CONTROLLED STUDY; DNA ADDUCT; DRUG CYTOTOXICITY; DRUG DNA BINDING; DRUG EXPOSURE; DRUG SENSITIVITY; GAMMA RADIATION; IMMUNOCYTOCHEMISTRY; MOUSE; MULTIMODALITY CANCER THERAPY; NONHUMAN; PRIORITY JOURNAL; RADIATION EXPOSURE; RADIOSENSITIVITY; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; DNA ADDUCTS; MICE; ORGANOPLATINUM COMPOUNDS; RADIATION-SENSITIZING AGENTS; TUMOR CELLS, CULTURED;

ANIMALIA; MURINAE;

EID: 0031446578     PISSN: 09553002     EISSN: None     Source Type: Journal    
DOI: 10.1080/095530097142834     Document Type: Article

References (47)

1. ALVAREZ, V., COBREROS, G., HERAS, A. and LOPEZ ZUMEL, C., 1978, Studies on cis-dichlorodiammineplatinum (II) as a radiosensitizer. British Journal of Cancer, 37, 68-72.
2. ANDREWS, P. A., SCHIEFER, M. A., MURPHY, M. P. and HOWELL, S. B., 1988, Enhanced potentiation of cisplatin cytotoxicity in human ovarian carcinoma cells by prolonged glutathione depletion. Chemico-Biological Interactions, 65, 51-58.
3. BEGG, A. C., 1990, Cisplatin and radiation: interaction probabilities and therapeutic possibilities. International Journal of Radiation Oncology, Biology, Physics, 19, 1183-1189.
4. BEGG, A. C., STEWART, F. A., DEWIT, L. and BARTELINK, H., 1990, Interactions between cisplatin and radiation in experimental rodent tumors and normal tissues. In Antitumor Drug Radiation Interactions, edited by B. T. Hill and A. S. Bellamy (Florida: CRC Press, Boca Raton), pp. 153-170.
5. BEGG, A. C., STEWART, F. A., DEWIT, L. and BARTELINK, H., 1988, Cisplatin-radiation interactions in tumours and normal tissues. In Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, edited by M. Nicolini (Boston: Martinus Nijhoff), pp. 74-80.
6. BEGG, A. C., VAN DER KOLK, P. J., DEWIT, L. and BARTELINK, H., 1986. Radiosensitization by cisplatin of RIF1 tumour cells in vitro. International Journal of Radiation Biology, 50, 871-884.
7. BEGG, A. C., VAN DER KOLK, P. J., EMONDT, J. and BARTELINK, H., 1987b, Radiosensitization in vitro by cis-diamminel(1,1-cyclobutanedicarboxylato) platinum (II) (Carboplatin, JM8) and ethylenediammine-malonatoplatinum(II) (JM40). Radiotherapy and Ontology, 9, 157-165.
8. BYFIELD, J. E. and CALABRO-JONES, P. M., 1981, Carrier-dependent and carrier-independent transport of anticancer alkylating agents. Nature, 294, 281-283.
9. BYHARDT, R. W., SCOTT, C. B., ETTINGER, D. S. and CURRAN, W. J., 1995, Concurrent hyperfractionated irradiation and chemotherapy for unresectable non small cell lung cancer. Cancer, 75, 2337-2344.
10. CHEN, G., FREI, E. and ZELLER, W. J., 1989, Determination of intracellular reduced glutathione and glutathione related enzyme activities in cisplatin-sensitive and resistant experimental ovarian carcinoma cell lines. Cancer Letters, 46, 207-211.
11. CHOUGULE, P. B., SUK, S., CHU, Q. D. and LEONE, L., 1994, Cisplatin as a radiation sensitizer in the treatment of advanced head and neck cancers. Cancer, 74, 1927-1932.
12. CLARK, E. P. and EPP, E. R., 1983, The role of thiols in cellular response to radiation and drugs. Radiation Research, 95, 437-455.
13. DE POOTER, C. M. J., SCALLIET, P. G., ELST, H. J. and HUYBRECHT, J. J., 1991, Resistance patterns between cis-diamminedichloroplatinum(II) and ionizing radiation. Cancer Research, 51, 4523-4527.
14. DOUPLE, E. B., O'HARA, J. A. and WANG, H., 1995, Production of DNA double-strand breaks by interactions between carboplatin and radiation: a potential mechanism of radiopotentiation. Radiation Research, 143, 309-315.
15. DOUPLE, E. B. and RICHMOND, R. C., 1982, Enhancement of the potentiation of radiotherapy by platinum drugs in a mouse tumor. International Journal of Radiation Oncology, Biology, Physics, 8, 501-503.
16. EICHHOLTZ-WIRTH, H. and HIETEL, B., 1994, Cisplatin resistance in mouse fibrosarcoma cells after low-dose irradiation in vitro and in vivo. British Journal of Cancer, 70, 579-584.
17. ELLMAN, G. L., 1959. Tissue sulfhydryl groups. Archives of Biochemistry and Biophysics, 82, 70-77.
18. FICHTINGER-SCHEPMAN, A. M. J., VAN DIJK-KONIJNENBURG, H. C. and DIJT, F. J., 1994, Effects of thiourea and ammonium bicarbonate on the formation and stability of bifunctional cisplatin-DNA adducts: consequences for the accurate quantification of adducts in (cellular) DNA. Journal of Inorganic Biochemistry, 58, 177-191.
19. GATELY, D. P. and HOWELL, S. B., 1993, Cellular accumulation of the anticancer agent cisplatin: a review. British Journal of Cancer, 67, 1171-1176.
20. ISHIKAWA, T. and ALI-OSMAN, F., 1993, Glutathione-associated cis-diamminedichloroplatinum (II) metabolism and ATP-dependent efflux from leukemia cells. Journal of Biological Chemistry, 268, 20116-20125.
21. KALLMAN, F. R., PAPACCHIETTA, D. and ZAGHLOUL, M. S., 1991, Schedule-dependent therapeutic gain from the combination of fractionated irradiation plus cDDDP and 5-FU or plus cDDP and cyclophosphamide in C3H/Km mouse model systems. International Journal of Radiation Oncology, Biology, Physics, 20, 227-232.
22. KELLAND, L. R., ABEL, G., MCKEAGE, M. J. and JONES, M., 1993, Preclinical antitumor evaluation of bis-acetatoammine-dichlor-cyclohexylamine Platinum(IV): orally active platinum drug. Cancer Research, 53, 2581-2586.
23. KELLAND, L. R. and MCKEAGE, M. J., 1994. New platinum agents. A comparison in ovarian cancer. Drugs and Aging, 5, 85-95.
24. KNOX, R. J., FRIEDLOS, F., LYALL, D. A. and ROBERTS, J. J., 1986, Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato) platinum(II) differ only in their kinetics of their reaction with DNA. Cancer Research, 46, 1972-1979.
25. LOWRY, O. H., ROSENBROUGH, N. J., FARR, A. L. and RANDALL, R. J., 1951, Protein measurement with folin phenol reagent. Journal of Biological Chemistry, 193, 265-275.
26. MCKEAGE, M. J., MISTRY, P., WARD, J. and BOXALL, F. E., 1995, A phase I and pharmacology study of an oral platinum complex. JM216: dose-dependent pharmacokinetics with single-dose administration. Cancer Chemotherapy and Pharmacokinetics, 36, 451-458.
27. MELLISH, K. J., BARNARD, C. F. J., MURRER, B. A. and KELLAND, L. R., 1995, DNA-binding properties of novel cis- and trans platinum-based anticancer agents in 2 human ovarian carcinoma cell lines. International Journal of Cancer, 62, 717-723.
28. MUGGIA, F. M., 1991, Introduction: Cisplatin update. Seminars in Oncology, 18, 1-4.
29. O'HARA, J. A., DOUPLE, E. B. and RICHMOND, R. C., 1986, Enhancement of radiation-induced cell kill by platinum complexes (carboplatin). Journal of Radiation Oncology, Biology, Physics, 12, 1419-1422.
30. ORTA, T., EADY, J. J., PEACOCK, J. H. and STEEL, G. G., 1995, Glutathione manipulation and the radiosensitivity of human tumor and fibroblast cell lines. International Journal of Radiation Biology, 68, 413-419.
31. PITCHARD, R. S. and ANTHONY, S. P., 1996, Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small cell lung cancer. Annals of Internal Medicine, 125, 723-729.
32. RAYNAUD, F. I., MISTRY, P., DONAGHAU, A., POON, G. K., KELLAND, L. R., BARNARD, C. F., MURRER, B. A. and HARRAP, K. R., 1996a, Biotransformation of the platinum drug JM216 following oral administration to cancer patients. Cancer Chemotherapy and Pharmacology, 38, 155-162.
33. RAYNAUD, F. I., ODELL, D. E. and KELLAND, L. R., 1996b, Intracellular metabolism of the orally active platinum drug JM216: influence of glutathione levels. British Journal of Cancer, 74, 380-386.
34. ROSENBERG, B., 1985, Fundamental studies with cisplatin. Cancer, 55, 2303-2316.
35. SAWAYA, R., TOFILON, P. J., MOHANAM, S. and ALI-OSMAN, F., 1994, Induction of tissue-type plasminogen activator and 72-kDa type-IV collagenase by ionizing radiation in rat astrocytes. International Journal of Cancer, 56, 214-218.
36. SCHAAKE-KONING, C., VAN DEN BOGEART, D., DALESIO, O. and FESTEN, J., 1992, Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell-lung cancer. New England Journal of Medicine, 326, 524-530.
37. SCHUSTER-UITTERHOEVE, L., VAN DE VAART, P. J. M., SCHAAKE-KONING, C. and BENRAADT, J., 1996, Feasibility of escalating daily doses of cisplatin in combination with accelerated radiotherapy in non small cell lung cancer. European Journal of Cancer, 32A, 1314-1319.
38. SKOV, K. and MACPHAIL, S., 1991, Interaction of platinum drugs with clinically relevant x-ray doses in mammalian cells: a comparison of cisplatin, carboplatin, iproplatin, and tetraplatin. International Journal of Radiation Oncology, Biology, Physics, 20, 221-225.
39. TEICHER, B. A. and HOLDEN, S. A., 1987, Antitumor and radiosensitizing activity of several platinum-(+) dye complexes. Radiation Research, 109, 58-67.
40. TERHEGGEN, P. M. A. B., EMONDT, J. Y., FLOOT, B. G. J. and DIJKMAN, R., 1990, The correlation between cell killing by cis-diamminedichloroplatinum(II) in six mammalian cell lines and binding of a cis-diamminedichloroplatinum(II)-DNA antiserum. Cancer Research, 50, 3556-3561.
41. TERHEGGEN, P. M. A. B., FLOOT, B. G. J., LEMPERS, E. L. M., VAN TELLINGEN, O., BEGG, A. C. and DEN ENGELSE, L., 1991, Antibodies against cisplatin-modified DNA and cisplatin-modified (di)nucleotides. Cancer Chemotherapy and Pharmacology, 28, 185-191.
42. TERHEGGEN, P. M. A. B., FLOOT, B. G. J., SCHERER, E. and BEGG, A. C., 1987, Immunocytochemical detection of interaction products of cis-diamminedichloroplatinum(II) and cis-diammine(1,1 cyclobutanedicarboxylato) platinum-(II) with DNA in rodent tissue sections. Cancer Research, 47, 6719-6725.
43. TWENTYMAN, P. R., BROWN, J. M., GRAY, J. W. and FRANKO, A. J., 1980, A new mouse tumor model system (RIF-1) for comparison of endpoint studies. Journal of the National Cancer Institute, 64, 595-604.
44. TWENTYMAN, P. R., KALLMAN, R. F. and BROWN, J. M., 1979, The effect of time between X-irradiation and chemotherapy on the growth of three solid mouse tumours III isdiamminedchloroplatinum. International Journal of Radiation Oncology, Biology, Physics, 5, 1365-1367.
45. WEITBERG, A. B., YASHAR, J., GLICKSMAN, A. S. and POSNER, M., 1993, Combined modality therapy for stage IIIA non-small cell carcinoma of the lung. European Journal of Cancer, 29A, 511-512.
46. YANG, L. X., DOUPLE, E. B., O'HARA, J. A. and CRABTREE, R. A., 1995, Enhanced radiation-induced cell killing by carboplatin in cells of repair-proficient and repair-deficient cell lines. Radiation Research, 144, 230-236.
47. YANG, L. X., DOUPLE, E. B., O'HARA, J. A. and WANG, H., 1995, Production of DNA double-strand breaks by interactions between carboplatin and radiation: a potential mechanism of radiopotentiation. Radiation Research, 143, 309-315.